Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

August 10, 2015

Primary Completion Date

September 12, 2017

Study Completion Date

September 12, 2017

Conditions
COPD
Interventions
DRUG

BGF MDI 320/14.4/9.6 μg

Budesonide, Glycopyrronium, and Formoterol Fumarate

DRUG

GFF MDI 14.4/9.6 μg

Glycopyrronium and Formoterol Fumarate

DRUG

BFF MDI 320/9.6 μg

Budesonide and Formoterol Fumarate

Trial Locations (64)

23225

Research Site, Richmond

23230

Research Site, Richmond

23606

Research Site, Newport News

24210

Research Site, Abingdon

26505

Research Site, Morgantown

27103

Research Site, Winston-Salem

27408

Research Site, Greensboro

28054

Research Site, Gastonia

28117

Research Site, Mooresville

28207

Research Site, Charlotte

28401

Research Site, Wilmington

28739

Research Site, Hendersonville

29303

Research Site, Spartanburg

29379

Research Site, Union

29406

Research Site, Charleston

29464

Research Site, Mt. Pleasant

29615

Research Site, Greenville

29621

Research Site, Anderson

29640

Research Site, Easley

29678

Research Site, Seneca

29707

Research Site, Old Point Station

29732

Research Site, Rock Hill

30019

Research Site, Dacula

30071

Research Site, Norcross

31326

Research Site, Rincon

32174

Research Site, Ormond Beach

32503

Research Site, Pensacola

32789

Research Site, Winter Park

33186

Research Site, Miami

33321

Research Site, Tamarac

33603

Research Site, Tampa

33756

Research Site, Clearwater

35501

Research Site, Jasper

36303

Research Site, Dothan

37601

Research Site, Johnson City

43016

Research Site, Dublin

43213

Research Site, Columbus

43235

Research Site, Columbus

45231

Research Site, Cincinnati

45242

Research Site, Cincinnati

45245

Research Site, Cincinnati

45459

Research Site, Dayton

55125

Research Site, Woodbury

55402

Research Site, Minneapolis

55407

Research Site, Minneapolis

55435

Research Site, Edina

63141

Research Site, St Louis

63301

Research Site, Saint Charles

73103

Research Site, Oklahoma City

75604

Research Site, Longview

77339

Research Site, Kingwood

78229

Research Site, San Antonio

85018

Research Site, Phoenix

85381

Research Site, Peoria

87108

Research Site, Albuquerque

89106

Research Site, Las Vegas

89503

Research Site, Reno

90274

Research Site, Rolling Hills Estates

92064

Research Site, Poway

92835

Research Site, Fullerton

95670

Research Site, Gold River

95821

Research Site, Sacramento

97504

Research Site, Medford

98405

Research Site, Tacoma

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY